Current Assets
Accounts Receivable
Vertex Pharmaceuticals Accounts Receivable increased by 5.5% to $2.05B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 27.6%, from $1.61B to $2.05B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 18.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ3 2015
Last reportedQ4 2025
How to read this metric
An increase relative to sales may signal slowing collections or credit risk, while a decrease suggests efficient cash conversion.
Detailed definition
The total amount of credit extended to customers and channel partners for products sold or services rendered, minus an a...
Peer comparison
Typically scales with revenue growth; however, companies with strong direct-to-consumer channels may have lower receivables relative to those relying on third-party distributors.
Metric ID:
accounts_receivable_netHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $929.14M | $1.10B | $1.14B | $1.29B | $1.33B | $1.39B | $1.44B | $1.55B | $1.56B | $1.54B | $1.56B | $1.79B | $1.66B | $1.75B | $1.61B | $1.81B | $1.89B | $1.95B | $2.05B |
| QoQ Change | — | +18.4% | +3.3% | +13.7% | +3.1% | +3.9% | +4.1% | +7.3% | +0.5% | -1.1% | +1.6% | +14.7% | -7.6% | +5.7% | -8.1% | +12.2% | +4.9% | +2.8% | +5.5% |
| YoY Change | — | — | — | — | +43.5% | +25.9% | +26.9% | +19.7% | +16.8% | +11.1% | +8.4% | +15.9% | +6.4% | +13.8% | +2.9% | +0.7% | +14.3% | +11.2% | +27.6% |
Range$929.14M – $2.05B
CAGR+19.3%
Avg YoY Growth+16.3%
Median YoY Growth+14.3%
Current Streak4 quarters growth
Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's accounts receivable?
- Vertex Pharmaceuticals (VRTX) reported accounts receivable of $2.05B in Q4 2025.
- How has Vertex Pharmaceuticals's accounts receivable changed year-over-year?
- Vertex Pharmaceuticals's accounts receivable increased by 27.6% year-over-year, from $1.61B to $2.05B.
- What is the long-term trend for Vertex Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's accounts receivable has grown at a 18.3% compound annual growth rate (CAGR), from $885.35M to $2.05B.
- What does accounts receivable mean?
- The amount of money customers owe the company for products they have already received.